Table 6. Univariable analysis of explored factors for seroconversion for the wild-type and Omicron variants.
| Factors | Wild Type | Omicron Variant | ||||
|---|---|---|---|---|---|---|
| Seroconversion n (%) | OR (95% CI) | p Value | Seroconversion n (%) | OR (95% CI) | p Value | |
| Sex | ||||||
| male | 36 (80.00) (n = 45) | 1.39 (0.53–3.64) | 0.670 | 29 (64.44%) (n = 46) | 1.26 (0.54–2.92) | 0.578 |
| female | 34 (73.91%) (n = 46) | ref | - | 27 (58.70%) (n = 45) | ref | - |
| Age | ||||||
| <65 yrs | 47 (81.03%) (n = 58) | 1.70 (0.63–4.57) | 0.286 | 36 (62.07%) (n = 58) | 1.22(0.52–2.88) | 0.638 |
| ≥65 yrs | 25 (71.43%) (n = 35) | ref | - | 20 (57.14%) (n = 35) | ref | - |
| Smoking (yes) | 16 (84.21%) (n = 19) | 1.68 (0.44–6.44) | 0.447 | 12 (63.16%) (n = 19) | 1.14 (0.40–3.23) | 0.801 |
| BMI | ||||||
| <18.5 (underweight) | 9 (100%) (n = 9) | 7.94 (0.42–148.19) | 0.165 | 8 (88.89%) (n = 9) | 3.73 (0.58–23.78) | 0.163 |
| 18.5–22.9 (normal) | 34 (79.07%) (n = 43) | 1.51 (0.56–4.10) | 0.410 | 24 (55.81%) (n = 43) | 0.82 (0.34–1.98) | 0.674 |
| ≥23.0 (overweight) | 27 (71.05%) (n = 38) | ref | - | 23 (60.53%) (n = 38) | ref | - |
| Primary cancer, n (%) | ||||||
| GI vs. non-GI | 25 (78.12%) (n = 32) | 1.04 (0.37–2.91) | 0.938 | 19 (59.38%) (n = 32) | 0.92 (0.38–2.20) | 0.857 |
| HBP vs. non-HBP | 13 (81.25%) (n = 16) | 1.30 (0.33–5.07) | 0.706 | 10 (62.50%) (n = 16) | 1.09 (0.36–3.33) | 0.867 |
| Breast vs. nonbreast | 18/26, 69.23% (n = 26) | 0.53 (0.19–1.48) | 0.229 | 14 (53.85%) (n = 26) | 0.67 (0.27–1.69) | 0.406 |
| Prostate vs. nonprostate | 3 (60.00%) (n = 5) | 0.40 (0.06–2.61) | 0.344 | 1 (20.00%) (n = 5) | 0.14 (0.01–1.37) | 0.093 |
| Others vs. nonother | 13 (92.86%) (n = 14) | 4.40 (0.54–35.85) | 0.166 | 13 (92.86%) (n = 14) | 10.34 (1.28–82.92) | 0.028 |
| Metastasis | 36 (81.82%) (n = 44) | 1.72 (0.63–4.66) | 0.286 | 28 (63.64%) (n = 44) | 1.18 (0.50–2.76) | 0.691 |
| Active cancer treatment | 51 (71.83%) (n = 71) | 0.13 (0.01–1.07) | 0.058 | 41 (57.75%) (n = 71) | 0.45 (0.14–1.39) | 0.167 |
| Chemo vs. nonchemo | 31 (75.61%) (n = 41) | 0.87 (0.32–2.43) | 0.788 | 24 (58.54%) (n = 41) | 0.79 (0.34–1.85) | 0.594 |
| Targeted vs. nontargeted | 11 (57.89%) (n = 19) | 0.30 (0.10–0.90) | 0.032 | 10 (52.63%) n = 19) | 0.62 (0.22–1.74) | 0.372 |
| Hormonal vs. nonhormonal | 8 (57.14%) (n = 14) | 0.32 (0.09–1.07) | 0.064 | 5 (35.71%) (n = 14) | 0.28 (0.08–0.93) | 0.038 |
| No active cancer treatment | 19 (95.00%) (n = 20) | ref | - | 15 (75.00%) (n = 20) | ref | - |
| Comorbidity | ||||||
| DM | 11 (64.71%) (n = 17) | 0.45 (0.14–1.43) | 0.181 | 10 (58.82%) (n = 17) | 0.90 (0.30–2.63) | 0.848 |
| HT | 24 (68.57%) (n = 35) | 0.46 (0.17–1.24) | 0.128 | 18 (51.43%) (n = 35) | 0.52 (0.22–1.25) | 0.148 |
| Other comorbid | 30 (73.175%) (n = 41) | 0.66 (0.25–1.76) | 0.414 | 26 (63.41%) (n = 41) | 1.21 (0.52–2.82) | 0.654 |
| Vaccine type | ||||||
| mRNA+mRNA | 40 (93.02%) (n = 43) | 14.76 (4.06–53.65) | <0.001 | 32 (74.42%) (n = 43) | 6.99 (2.54–19.19) | <0.001 |
| non-mRNA+mRNA | 19 (100.00%) (n = 19) | 49.75 (2.76–895.38) | 0.008 | 16 (84.21%) (n = 19) | 11.66 (2.94–46.24) | <0.001 |
| Non-mRNA+non-mRNA | 14 (43.75%) (n = 32) | Reference | 9 (28.12%) (n = 32) | Reference | ||
| Leucopenia | 11 (73.33%) (n = 15) | 0.65 (0.16–2.52) | 0.535 | 10 (66.67%) (n = 15) | 1.35 (0.40–4.60) | 0.624 |
| Neutropenia | 2 (40.00%) (n = 5) | 0.14 (0.02–0.96) | 0.046 | 2 (40.00%) (n = 5) | 0.38 (0.06–2.51) | 0.332 |
| Lymphopenia | 14 (70.00%) (n = 20) | 0.46 (0.12–1.63) | 0.234 | 12 (60.00%) (n = 20) | 0.92 (0.31–2.74) | 0.886 |
BMI = body mass index (mg/m2), GI = gastrointestinal cancer, HBP = hepatobiliary-pancreatic cancer, DM = diabetes mellitus, HT = hypertension